Related Experiment Video
Updated: Jul 17, 2025
09:29
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
17.7K
Updated Austrian treatment algorithm for metastatic triple-negative breast cancer
Rupert Bartsch1, Gabriel Rinnerthaler2, Edgar Petru3
1Department of Medicine I, Division of Oncology, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria.
Wiener Klinische Wochenschrift
|September 8, 2023
Summary
Triple Negative Breast Cancer (TNBC) has poor outcomes. Experts reviewed therapies, including sacituzumab govitecan, to improve treatment for metastatic TNBC patients.
Area of Science:
- Oncology
- Medical Research
Background:
- Triple Negative Breast Cancer (TNBC) accounts for 15% of diagnoses.
- TNBC presents a higher risk of recurrence and metastasis, particularly to the brain.
- Limited therapeutic advancements have been made for TNBC compared to other subtypes.
Purpose of the Study:
- To establish a clinical risk-benefit profile for available metastatic TNBC (mTNBC) therapies.
- To discuss the potential role of sacituzumab govitecan in the TNBC treatment algorithm.
Main Methods:
- Expert meeting convened by Austrian breast cancer specialists.
- Comprehensive review of existing mTNBC treatment options.
- Discussion focused on clinical risk-benefit assessments.
Main Results:
- The abstract does not contain specific results from the expert meeting.
- The focus was on evaluating current therapies and the potential of sacituzumab govitecan.
Conclusions:
- There is a need for improved treatment strategies for TNBC.
- Sacituzumab govitecan is being considered for its role in the mTNBC treatment landscape.
Related Concept Videos
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K